Ultragenyx Pharmaceutical RARE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $93M-36.2% | $145.79M+30.2% | $111.94M-7.0% | $120.41M+16.9% | $103M-11.1% | |
| Non Cash Royalty | $20M-46.8% | $37.58M+50.9% | $24.91M-17.8% | $30.32M+59.6% | $19M-43.4% | |
| Royalty | $47M-55.5% | $105.6M+62.6% | $64.94M-24.2% | $85.68M+78.5% | $48M-48.5% | |
| Royalty Percentage On Net Sales by Geography | ||||||
| European Union And Switzerland And Turkey | 10%— | —— | —— | —— | 10%— | |
| Royalty Revenue For Sales In North American Territiory | 30%— | —— | —— | —— | —— | |
| Revenue by Geography | ||||||
| Asia Pacific | $4M-25.4% | $5.36M+4.0% | $5.15M+22.7% | $4.2M+40.0% | $3M-17.6% | |
| EMEA | $31M+2.0% | $30.39M+9.0% | $27.88M+5.6% | $26.4M+14.8% | $23M-10.3% | |
| Latin America | $42M+8.3% | $38.78M-10.6% | $43.36M+31.5% | $32.97M-40.1% | $55M+192% | |
| North America | $59M-55.6% | $132.75M+58.9% | $83.54M-18.8% | $102.93M+77.5% | $58M-50.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.